July 14, 2026. MINNEAPOLIS--HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. The Edison System is a novel, non-invasive, image guided platform that is intended for...Read the Full Article
LOS ANGELES, July 13, 2026--Nervonik, Inc., a medical technology company developing a next-generation peripheral nerve stimulation platform for chronic pain, today announced it is expanding its leadership team with the addition of several experienced medical device and neuromodulation leaders – Rob DiTota, Dan Brounstein, and Patrick Martin – as the company moves...Read the Full Article
July 8, 2025 KIRKLAND, Wash.-Cardiac Dimensions, a leader in transcatheter therapies for heart failure, today announced the publication of three major manuscripts that together form the most comprehensive evidence base ever assembled for transcatheter indirect mitral annuloplasty. These publications span a five-year multi-center commercial registry, the largest single-center experience across both preserved...Read the Full Article
350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes MINNEAPOLIS, July 08, 2026 – Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced that the ReCET Clinical...Read the Full Article
Values Company at $3.75 Billion and Funds Development of Additional Clinical Applications MINNEAPOLIS, June 22, 2026—HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the closing of a new financing round with participation from Reed Jobs and Yosemite, whose aim is to “make cancer non-lethal in...Read the Full Article
Round led by Lumira Ventures and Roche Venture Fund with new investment from Sanofi CHICAGO, June 18, 2026 - COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today it has closed a $50 million Series B funding round led by existing investors Lumira Ventures...Read the Full Article
Financing co-led by BVF Partners L.P. and RA Capital Management, with participation from new and existing investors. Proceeds will support the late-stage development of NES/T Gel, an investigational, daily, hormonal, reversible male contraceptive with first-in-class potential, as well as other pipeline assets. Charlottesville, VA: Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male...Read the Full Article
WATERTOWN, Mass.--Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced the appointment of Vineet Agarwal, MBA as Chief Business Officer. Mr. Agarwal is a recognized life sciences leader, operator and advisor with nearly two decades of experience in company creation, capital formation,...Read the Full Article
MINNEAPOLIS- HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking authorization to expand the use of its Edison® Histotripsy System to include the destruction of kidney (renal) tumors. This milestone marks...Read the Full Article
- Topline results expected Q3 2026 WATERTOWN, Mass.--Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that its Phase 2b ASPIRE trial evaluating taplucainium for the treatment of refractory or unexplained chronic cough (rCC/uCC) is fully enrolled. “Fully enrolling the Phase 2b...Read the Full Article
LOS ANGELES, April 27, 2026 -- Nervonik, Inc., a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, today announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and...Read the Full Article
Patient dosing commenced in Wave II, a multicenter Phase 2/3 study evaluating THRV-1268 in genetically confirmed Long QT Syndrome (LQTS) Type 2; enrollment at leading centers throughout the United States is advancing on track. FDA Fast Track Designation granted for THRV-1268 in LQTS Type 2 and Type 3, supporting expedited development of...Read the Full Article
MINNEAPOLIS--HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital...Read the Full Article
Arboretum Ventures leads financing, with participation from existing investors, as Endogenex advances its novel treatment targeting a damaged duodenum as a driver of type 2 diabetes Minneapolis, March 25, 2026 – Endogenex, a clinical-stage medical technology company pioneering a new treatment for type 2 diabetes (T2D), today announced the closing of a $50...Read the Full Article
Tegavivint Targets the Central Oncogenic Driver in Colorectal Cancer as First-in-Class Clinical-Stage Wnt/β-Catenin Inhibitor CRC Expansion Builds on Promising Monotherapy Activity and Favorable Safety Profile Observed in Advanced Hepatocellular Carcinoma HOUSTON, March 25, 2026 -- Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today reported that the first patient...Read the Full Article
Peer-Reviewed Data Show Durable HbA1c Reduction, Significant Weight Loss, and a Favorable Safety Profile Through 48 Weeks Following a Single Endoscopic Procedure for Type 2 Diabetes MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), announced the...Read the Full Article
- Phase 1/1b clinical trial with CGX-926 ongoing for MC4R-deficient genetic obesity - - Programs in Parkinson's Disease and Alpha-1 antitrypsin deficiency progressing toward the clinic - MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics, a clinical-stage, computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d)...Read the Full Article
Funding will expand the range of Dualase® genome editors for new high morbidity and mortality genetic disease targets. TORONTO, March 18, 2026 - Specific Biologics Inc. ("Specific"), a biotechnology company developing industry-leading in vivo genome editing medicines to treat the untreatable, today announced that together with Western University ("Western") it was awarded a grant totaling over CAD$1.8 million...Read the Full Article
Trial met its primary safety and key prespecified secondary efficacy endpoints, supporting advancement into Phase 3 development in 2H 2026 DELRAY BEACH, Fla., Feb. 17, 2026 -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company developing novel treatments for smell and taste disorders, today announced positive topline results from its Phase 2 FLAVOR trial of...Read the Full Article
Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors Osteosarcoma Program Builds on Clinical Benefit observed in Lead Indication of Advanced Hepatocellular Carcinoma HOUSTON, Feb. 10, 2026 -- Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to revolutionizing the treatment of Wnt-driven cancers, today announced that the...Read the Full Article
Nocions™ are small molecule charged sodium channel blockers designed to selectively silence activated pain-sensing neurons while sparing normal sensation and motor function Approach enables broad inhibition of multiple sodium channels (NaV1.7, 1.8, 1.9) driving pathological pain, addressing redundancy that has limited single-target strategies WATERTOWN, Mass.--Nocion Therapeutics, Inc. a biopharmaceutical company developing novel small...Read the Full Article
TORONTO, ON – AmacaThera Inc., led by Co-Founder and CEO Mike Cook, has been named Emerging Company of the Year by Life Sciences Ontario, recognizing the company’s pioneering advancements in drug delivery technology and its growing impact within the life sciences sector. At the core of AmacaThera’s innovation is its proprietary hydrogel...Read the Full Article
Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and reinforced by significant QTcF reductions observed in a subsequent clinical study with THRV-1268. Individuals and families affected by Long...Read the Full Article
Topline results from the ASPIRE Phase 2b study expected in mid-2026 with operating runway through 2027 Series B extension was led by Arkin Bio Capital and Monograph Capital, with participation from BioInnovation Capital, Canaan Partners, F-Prime Capital, Lumira Ventures, Mass General Brigham Ventures, Mission BioCapital, Morningside, Osage University Partners, and an undisclosed...Read the Full Article
Study demonstrated clear target engagement at both tested doses Potential for THRV-1268 to address prolonged QTcF in cardiometabolic diseases Phase 2a ASPIRE-HF study to commence enrollment in 2026 MONTREAL, Dec. 17, 2025 - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias and cardiometabolic diseases,...Read the Full Article
TORONTO, Dec. 16, 2025 - Specific Biologics Inc. ("Specific Biologics"), a precision in vivo genome editing company developing highly predictable, efficient and specific Dualase® genome editors to treat the untreatable, today announced the appointment of Dr. Richard Glickman to its Board of Directors. Dr. Glickman is an accomplished biotechnology executive and serial entrepreneur, with a career spanning...Read the Full Article
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1] SpectraWAVE’s technologies have the potential to significantly increase adoption of coronary...Read the Full Article
Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year Robert Meehan, M.D., appointed as Chief Medical Officer, bringing extensive clinical development expertise to advance the Company’s radiotherapeutic pipeline BOSTON, Mass. and VANCOUVER, British Columbia, December 4, 2025...Read the Full Article
Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the appointment of Matt Killeen, PhD, as Chief Business Officer (CBO). In this role, Dr. Killeen joins Thryv's senior leadership team and will...Read the Full Article
Iterion Therapeutics, a clinical-stage biopharmaceutical company, has been awarded a $7.1 million Product Development Research Grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the advancement of its lead candidate, tegavivint, into a Phase 2 clinical trial for patients with advanced hepatocellular carcinoma (HCC). The grant (ID: DP260243),...Read the Full Article
Low rates of treatment-related adverse events (42%) and dose interruptions (1.6%) Emerging detalimogene profile supports potential first line use in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CIS LEGEND trial pivotal cohort completed enrollment with 125 patients, exceeding target enGene to host conference call and webcast at 8:00 a.m. ET...Read the Full Article
AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera's long-acting non-opioid anesthetic for post-operative pain AMT-143 leverages AmacaThera's breakthrough tunable hydrogel platform, delivering sustained local release of ropivacaine AmacaThera and Pacira will collaborate on the Phase 2 clinical program, and Pacira will fund clinical development, manufacturing, and...Read the Full Article
-- The X1™ software, available as an add-on application to the HyperVue™ Imaging System, enables the first and only platform in the US combining angiogram-derived physiology and intravascular imaging on a single system -- SpectraWAVE Receives 510(k) Clearance for X1-FFR, an AI-enabled, Wire-Free, Drug-Free, Single Angiogram Physiology Solution -- The X1™ software,...Read the Full Article
With backing from Peter Thiel, K5 Global, Jeff Bezos, and Wellington Management, among others, HistoSonics is positioned to expand globally across new clinical applications Video of HistoSonics Edison Histotripsy System Video credit: HistoSonics MINNEAPOLIS--HistoSonics, Inc., the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the closing of...Read the Full Article
Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene’s clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral...Read the Full Article
https://www.youtube.com/watch?v=jVDIZH-OIocRead the Full Article
MONTREAL, Sept. 22, 2025 — Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, today announced that Fierce Biotech has named it as one of 2025’s Fierce 15 biotechnology companies, honoring it as one of the most innovative and promising private biotechnology companies in the...Read the Full Article
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity;CTA to be filed in 2H 2025 MONTREAL, Sept. 4, 2025 / -- Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity, GBA1-driven Parkinson's disease and Alpha-1 antitrypsin (A1AT) deficiency, announced today the closing...Read the Full Article
Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achieved enGene plans to provide an update from LEGEND’s pivotal cohort in 4Q 2025 Biologic License Application (BLA) submission planned for 2H 2026 BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company,...Read the Full Article
Prominent heart failure cardiologist Dr. William Abraham to play pivotal role in the advancement of the Carillon Mitral Contour System® to heart failure patients with FMR. Dr. William T. Abraham, Chief Medical Officer at Cardiac Dimensions KIRKLAND, Wash. - Cardiac Dimensions®, a leader in transcatheter therapies for heart failure, announced today the...Read the Full Article
Study Achieves Primary and all Secondary Endpoints Demonstrating Clinically Meaningful, Statistically Significant Improvements in hrHPV Negativity at Week 12 as Compared to Placebo 46% of Patients Treated with 3mg Cumulative Dose for Two Weeks Demonstrated Negativity for hrHPV at Week 12 as Compared to 16% for Placebo Group ABI-2280 Efficacy was Durable,...Read the Full Article
Acquisition will Accelerate Global Expansion of Company’s Breakthrough Edison® Histotripsy Platform and Non-Invasive Tumor Therapy MINNEAPOLIS – August 7, 2025 - HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced a management-led majority stake acquisition by a syndicate of globally recognized private and public investors, including...Read the Full Article
The Edison® System, developed by HistoSonics, uses focused ultrasound to mechanically destroy targeted tissue, including tumors, without surgery. Emma's experience, including her ability to go hiking the next day, highlights the non-invasive nature of the treatment and its potential to offer hope to patients with limited treatment options. https://vimeo.com/1085033284Read the Full Article
Founder Jeremy Brown, Ph.D. to continue as Chief Technical Officer, driving scientific vision HALIFAX, Nova Scotia — July 31, 2025 — Sound Blade Medical, Inc., a leader in handheld histotripsy therapy, today announced the appointment of Neil Barman, M.D. as Chief Executive Officer. Dr. Barman, a physician-executive with more than two decades...Read the Full Article
-Congruence's Revenir™ computational drug discovery engine has identified activators and correctors of GCase designed to target the key biological dysfunction in Parkinson's disease patients with GBA1 mutations- -Congruence plans to file an IND for its lead GCase program in 2026- MONTREAL, July 24, 2025 /PRNewswire/ -- Congruence, a computationally-driven biotechnology company building a unique...Read the Full Article
Building on the positive results of Phase 2 clinical trials in PSP and ALS, Transposon plans to initiate a Phase 2 clinical trial of TPN-101 for the treatment of Alzheimer's disease in Q4 2025 Concurrently, Transposon is advancing TPN-101 in the Phase 2/3 HEALEY ALS Platform trial SAN DIEGO, July 9, 2025 /PRNewswire/ -- Transposon...Read the Full Article
Philip Astley-Sparke, William Grossman and Michael Heffernan join the Board Management promotions strengthen clinical and regulatory operations Matthew Boyd named Chief Regulatory Officer, Jill Buck Chief Development Officer, and Katherine Chan Executive Director, Urology Clinical Lead BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral...Read the Full Article
Regenerative Medicine Advanced Therapy (RMAT) designation provides access to accelerated development tools Designation recognizes the potential of detalimogene to address significant unmet need BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA)...Read the Full Article
Existing investors provide funding to finish international RESPONDER-HF trial TEWKSBURY, MA – June 17, 2025 – Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the successful closure of a $55 million funding round from the company’s existing investment syndicate of Third Rock Ventures, General Catalyst Partners,...Read the Full Article
TORONTO, June 11, 2025 /CNW/ - Specific Biologics Inc., a biotechnology company advancing Dualase® genome editors for precise and programmable in vivo genome editing, today announced the appointment of Paul J. Hastings as Chair of its Board of Directors. Mr. Hastings is a distinguished leader in the biopharmaceutical industry and currently serves as Chief Executive Officer and Board...Read the Full Article